NDAORALCAPSULE, DELAYED REL PELLETS, TABLET
Approved
Nov 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREVACID NAPRAPAC 375 is a copackaged combination of lansoprazole (a proton pump inhibitor) and naproxen (an NSAID) designed to reduce the risk of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation. The lansoprazole protects the gastric mucosa while naproxen provides anti-inflammatory and analgesic effects. This fixed-dose combination targets patients with conditions such as osteoarthritis, rheumatoid arthritis, and other chronic pain conditions who are at risk for GI complications.
LOE Approaching
As a mature product approaching loss of exclusivity, this brand faces declining market opportunity and likely shrinking commercial infrastructure, signaling reduced hiring and team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PREVACID NAPRAPAC in its LOE-approaching phase means supporting a declining franchise with emphasis on market defense, generic transition planning, and channel management rather than growth initiatives. Career growth opportunities are limited; this role is better suited for professionals seeking stability in a maintenance capacity or those managing product lifecycle transitions.
Brand Manager
Worked on PREVACID NAPRAPAC 375 (COPACKAGED) at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.